What Ovitrelle Treats: Main Uses and Benefits

Ovitrelle is a recombinant form of the natural hormone human chorionic gonadotropin (hCG), which is applied across domains where additional symptomatic support is needed related to female infertility. Its main use is relevant in conditions characterized by periods of heightened symptoms related to reproductive challenges.

This medication is used in contexts involving heightened systemic burden for: women undergoing superovulation prior to assisted reproductive techniques (ART), such as in vitro fertilization (IVF), and anovulatory or oligo-ovulatory women who do not ovulate or who ovulate infrequently. In these scenarios, it assists with maintaining functional stability where additional management of discomfort is required after initial support of follicular growth.

The therapeutic approach contributes to improved comfort during periods of heightened symptoms related to reproductive challenges. The medication may be part of symptomatic management by easing the overall symptom load. This supportive relief is commonly used to help with conditions involving episodic or fluctuating manifestations of infertility.

---

Quick Fact: Supports Management of Symptoms of Systemic Imbalance

Regulatory References

1. EMA regulatory overview

Ovitrelle (choriogonadotropin alfa) is officially permitted for use in adult women who are either undergoing superovulation for Assisted Reproductive Technologies (ART) or who are anovulatory/oligo-ovulatory following follicular stimulation.

Contraindicated Populations (Must Not Use)

Official regulatory documents contraindicate Ovitrelle for use in the following populations and conditions:

• Patients with tumors of the hypothalamus, pituitary gland, ovary, uterus, or breast.
• Patients with active thromboembolic disorders (blood clotting problems).
• Women with primary ovarian failure or who are postmenopausal (where an effective response is not possible).
• Women with ovarian enlargement or cysts not caused by polycystic ovarian disease.
• Patients with gynaecological haemorrhages of unknown cause or known hypersensitivity to the drug or its excipients.
• Women with malformations of sexual organs or fibroid tumors of the uterus that are incompatible with pregnancy.
• Women with a history of extrauterine (ectopic) pregnancy in the previous three months.

Restricted or Conditional Use

Use is restricted or requires special precaution for patients with a high risk of Ovarian Hyperstimulation Syndrome (OHSS), where the medicine may be withheld. Patients with renal or hepatic impairment are also noted as groups for whom safety, efficacy, and pharmacokinetics have not been established.

Pregnancy and Lactation Status: Ovitrelle is not indicated for use during pregnancy or breastfeeding.

Interactions with other medicines and products

Official regulatory documents for Овитрель (Choriogonadotropin alfa) establish a specific interaction profile defined primarily by the absence of documented specific interactions with co-administered medicinal products, food, or common substances. This profile is consistent across major health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

---

Documented Interaction Profile Summary

Interaction Type	Regulatory Position (Choriogonadotropin Alfa)
Drug–Drug Interactions	None documented. Official labels do not list specific interactions with other medicines that require mandatory co-administration restrictions or dose adjustments.
Metabolic/Transporter Effects	None documented. There are no reports of pharmacokinetic interactions via specific CYP enzymes or drug transporters in regulatory text.
Food, Alcohol, or Herbal Products	None documented. Official labeling includes no restrictions or cautions regarding the co-administration of choriogonadotropin alfa with food, alcohol, or herbal products.
Contraindicated Combinations	None documented. No medicinal products are formally contraindicated for co-administration due to interaction risk.

---

Constraint Related to Diagnostic Procedures

The primary interaction-related caution documented in official labeling is the potential for interference with diagnostic testing. Due to the medicine's immunologic similarity to natural human Chorionic Gonadotropin (hCG), the administration of Choriogonadotropin alfa may interfere with the interpretation of serum or urinary hCG tests for a period of up to ten days following injection. This interference can result in a false positive pregnancy test result.

Agonism of the Luteinizing Hormone (LH) Receptor

Овитрель contains choriogonadotropin alfa, a substance that acts as a functional analog by binding to and activating the Luteinizing Hormone (LH) receptors located on the surface of ovarian follicular cells. This interaction mimics the naturally occurring LH surge, which is the physiological hormonal command necessary to initiate the final sequence of events within the ovarian structure. The drug's mechanism is defined by this direct and targeted agonism of a G protein-coupled receptor system.

---

Induction of Oocyte Maturation and Follicle Rupture Cascade

Following receptor activation, the drug triggers an intracellular cascade within the oocyte, leading to the resumption of meiosis, which finalizes the egg cell's maturation process. Simultaneously, the activated pathway signals the surrounding follicular cells to undergo structural changes, including the weakening and breakdown of the follicular wall. The culmination of this molecular cascade is the physical release of a mature egg from the ovary. The drug's pharmacodynamic action is complete once this targeted physiological modulation is achieved.

The administration of Ovitrelle (choriogonadotropin alfa) follows a specific protocol that defines a fixed, time-sensitive procedural step within assisted reproduction protocols. The medicine is supplied as a ready-to-use solution for injection within a pre-filled syringe, eliminating the requirement for complex preparation steps like dilution or reconstitution.

The singular authorized route of administration is by subcutaneous (SC) injection. This parenteral method dictates the technique for use, which may be conducted via self-administration after the patient receives comprehensive training and retains access to expert medical consultation.

---

Official Administration Guidelines

Instruction Domain	Requirement
Dosing Regimen	A single, fixed dose of 250 micrograms (mcg) is administered per treatment cycle. No dose titration or maintenance schedule exists.
Timing & Frequency	The injection is a one-time event per cycle, specifically timed to occur 24 to 48 hours after the final dose of the patient's preceding follicular stimulation agent.
Prerequisites for Use	Administration is conditional on clinical monitoring confirming optimal ovarian follicular development. The medicine is withheld if an excessive ovarian response is observed.
Population Rules	Dosing recommendations for patients with renal or hepatic impairment have not been established. There is no relevant use for this medicine in the pediatric population.

---

The usage pattern is characterized as single-use and acute, designed to execute the final step of the overall ovarian stimulation protocol. This strictly defined schedule establishes that the drug is not for daily or cyclical self-management, but rather a culminating, fixed event in a fertility plan. The entire procedural structure is designed to execute a final, single administration step within a larger, closely managed treatment protocol.

Овитрель: Recent Clinical Evidence

The research for Овитрель (choriogonadotropin alfa) focuses on its use as a trigger hormone in established fertility protocols, with evidence derived primarily from controlled clinical trials and comparative studies.

---

Evidence for Use in Assisted Reproductive Technologies (ART)

Research examining the use of Овитрель in women undergoing ART (e.g., In Vitro Fertilization) was conducted through randomized controlled trials (RCTs). These studies were structured to compare the recombinant hormone against urinary-derived products, monitoring measures like the number of mature eggs (oocytes) retrieved and early clinical pregnancy rates. Findings describe patterns where the measured outcomes for the recombinant product were functionally similar to those measured for the comparator studied in the populations. The primary RCTs focused on the events of a single treatment cycle.

---

Evidence for Use in Ovulation Induction (OI)

Овитрель was studied for use in anovulatory or oligo-ovulatory women who received prior follicular stimulation. Controlled clinical trials compared the recombinant hormone to the urinary-derived version, with the primary research focus being the measured rate of ovulation. Findings described patterns of functional equivalence. However, evidence is limited in this population by generally smaller sample sizes and short follow-up durations focused only on confirming the immediate ovulation event.

---

Research Design and Uncertainty

The evidence base is influenced by the study design, which relied on equivalence trials rather than comparison to an inactive control. This means findings describe patterns observed when comparing the recombinant product to an active comparator. The initial clinical trials had follow-up durations that were limited to a single cycle, and long-term effects are not fully established by these primary data sets. Furthermore, data for certain groups, such as women with severe renal or hepatic impairment, remain insufficient, and subgroup findings are uncertain when moving beyond the general infertile adult populations studied.

Key Studies & References

1. Ovitrelle (choriogonadotropin alfa) Summary of Product Characteristics (SmPC) Annex I – European Medicines Agency (EMA)
2. Ovidrel (choriogonadotropin alfa) U.S. Prescribing Information (Label) - DailyMed

Common questions about Овитрель (FAQ)

---

Q: How do I properly store Ovitrelle? Does it need to be refrigerated?

Official product information states that Ovitrelle must be stored in the refrigerator between 2 C and 8 C (36 F and 46 F) and must not be frozen. The pre-filled syringe may be kept out of the refrigerator at room temperature (up to 25 C) for a single period of no more than 30 days. As the medicine is intended for single use, any remaining solution in the syringe after the injection should be discarded immediately as per disposal instructions.

---

Q: How long after taking Ovitrelle will I ovulate or have my egg retrieval?

The purpose of Ovitrelle is to act as the final trigger to induce oocyte maturation and ovulation. Regulatory documents indicate that the maximum concentration of the active substance in the blood is typically reached between 12 and 24 hours after the injection. This peak concentration initiates the biological cascade leading to the final steps of egg maturation, which is timed to precede the scheduled egg retrieval or ovulation event.

---

Q: Does Ovitrelle cause a false-positive pregnancy test result?

Regulatory warnings indicate that administration of this medication may interfere with diagnostic testing. The active ingredient in Ovitrelle is immunologically similar to natural human Chorionic Gonadotropin (hCG), the hormone detected by pregnancy tests. Due to this similarity, official information states that it may lead to a false positive pregnancy test result for a period of up to 10 days following administration.

---

Q: What is the generic name or active chemical name for Ovitrelle?

The proprietary name for the medicine is Ovitrelle. The active substance contained in the pre-filled syringe is choriogonadotropin alfa. This is a recombinant (man-made) version of human Chorionic Gonadotropin (hCG).

---

Q: Can men use Ovitrelle to treat infertility?

According to the official product labeling, Ovitrelle is indicated for use in adult women who are undergoing specific fertility protocols, such as superovulation for Assisted Reproductive Technologies (ART). Official regulatory documents do not list an indication or approved use for this medicine in men to treat infertility.

---

Q: What specific type of injection is it, and what are the steps for self-administration?

The medicine is administered as a subcutaneous (SC) injection, meaning it is given just under the skin, usually in the lower abdomen or thigh. Official product information indicates that self-administration is possible after a patient has received comprehensive training from a healthcare professional and is following the detailed instructions provided in the medicine's official leaflet.

Storage and Disposal Requirements for Ovitrelle

To ensure product stability, Ovitrelle (choriogonadotropin alfa) must be stored in the refrigerator between 2 C and 8 C (36 F and 46 F). It is explicitly required not to freeze the medicine. The pre-filled syringe must be stored in its original container to protect it from light.

Stability and Child Safety

For patient convenience, the pre-filled syringe may be kept at room temperature, up to 25 C (77 F), for a single period of no more than 30 days. If this limit is exceeded, the product must be discarded. The medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Ovitrelle is for single use. The used syringe and needle must be disposed of immediately in an approved sharps container. Unused solution or waste material must not be thrown away via wastewater or household waste, but should be disposed of according to local regulatory requirements.